inexpensive, nontoxic manganese catalyst enabled unprecedented redox‐neutral carbonylative annulations under ambient pressure. The manganese catalyst outperformed all other typically used base and precious‐metal catalysts. The outstanding versatility of the manganese catalysis manifold was reflected by ample substrate scope, setting the stage for effective late‐stage manipulations under racemization‐free
The Pd(ii)-catalyzed pyridine-directed carbonylative cycloamidation of ketoimines has provided an efficient protocol for assembly of pyrido[1,2-a]pyrimidin-4-ones.
cross-coupling reactions of halo derivatives of 4H-pyrido[1,2-a]pyrimidin-4-one with (het)arylboronic acids allow easy access to (het)aryl and vinyl derivatives of this bicycle in good to excellent yields, even from chloro derivatives. The sequence of reactivity of the halogen in the different positions of the ring system was also investigated. 6-Phenyl-4H-pyrido[1,2-a]pyrimidin-4-one could be prepared by thermal
钯催化的卤素衍生物的Suzuki-Miyaura交叉偶联反应 4 H-吡啶并[1,2- a ]嘧啶-4-一与(杂)芳基硼酸一起使用,即使从氯代衍生物中也可以很容易地获得该自行车的(杂)芳基和乙烯基衍生物。还研究了卤素在环系统不同位置的反应顺序。6-苯基-4 H-吡啶并[1,2- a ]嘧啶-4-一 可以通过热环化制备 异亚丙基(6-苯基吡啶-2-基氨基)亚甲基丙二酸酯,以及少量的7-苯基-1,4-二氢-1,8-萘啶-4-酮。
Substituted pyrimidone derivatives
申请人:Sanofi-Aventis
公开号:EP2138493A1
公开(公告)日:2009-12-30
Pyrimidone derivatives of formula (I)
wherein:
R1 represents a 4-pyridine ring; R2 represents a hydrogen atom; R3 represents a hydrogen atom; R4 represents : a hydrogen atom; a phenyl ring, this ring being optionally substituted by 1 to 4 substituents selected from a C1-6 alkyl group, a halogen atom, a C1-2 halogenated alkyl group, a hydroxyl group, a C1-6 alkoxy group, a C1-2 halogenated alkoxy group, R5 represents a hydrogen atom, a C1-6 alkyl group, a 4-pyridine group, a phenyl group, these groups being optionally substituted, R6 represents a hydrogen atom, a C1-6 alkyl group, a benzyloxy group, a phenyl C1-6 alkyl group, these groups being optionally substituted, in form of a free base or of an addition salt with an acid.
Use in therapeutic.
Pyrimidone derivatives of formula (I)
wherein R1, R2, R3, R4, R5, and R6 are as defined in the disclosure. Also disclosed are methods of preparing the compounds of formula (I) and their use in therapeutics.